J.P. Morgan analyst Anupam Rama has maintained their bullish stance on NBIX stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Anupam Rama has given his Buy rating due to a combination of factors reflecting Neurocrine Biosciences’ potential for long-term growth. The company’s neuropsychiatry portfolio, including promising assets like osavampator (AMPA PAM mechanism) for major depressive disorder (MDD) and direclidine for schizophrenia, is seen as undervalued in the market. The pipeline’s breadth, which also includes early-stage developments in endocrinology focusing on conditions like obesity and congenital adrenal hyperplasia, supports the potential for significant upside.
Rama also emphasizes the anticipated pivotal data in 2027 for both osavampator and direclidine, with enrollment progressing well. Additionally, expert commentary highlights the favorable safety and efficacy profiles of these assets, addressing critical unmet needs in their respective therapeutic areas. The company’s strategic focus on diversified therapeutic areas, new modalities, and external innovation further strengthens its growth outlook, underpinning the positive rating recommendation.
NBIX’s price has also changed moderately for the past six months – from $125.000 to $148.740, which is a 18.99% increase.